miR-223-3p regulating the occurrence and development of liver cancer cells by targeting FAT1 gene

Jun Xu; Bei Wang; Zhengtao Liu; Mingchun Lai; Mangli Zhang; Shusen Zheng; Jun Xu; Bei Wang; Zhengtao Liu; Mingchun Lai; Mangli Zhang; Shusen Zheng

doi:10.3934/mbe.2020079

Mathematical Biosciences and Engineering

2020, Volume 17, Issue 2: 1534-1547. doi: 10.3934/mbe.2020079

Previous Article Next Article

Research article Special Issues

miR-223-3p regulating the occurrence and development of liver cancer cells by targeting FAT1 gene

1.
Department of Division of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China
2.
Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health, Hangzhou 310003, China
3.
Collaborative Innovation Center for Diagnosis Treatment of Infectious Diseases, Hangzhou 310003, China

Received: 29 May 2019 Accepted: 10 November 2019 Published: 03 December 2019

Objective To explore the mechanism of miR-223-3p regulating the occurrence and development of liver cancer cells by targeting FAT1 gene.

Methods Bioinformatics analysis was used to analyze the differentially expressed genes in liver cancer tissue chips. Forty-eight cases of liver cancer tissues and corresponding adjacent tissues were selected, and qRT-PCR was used to detect the expression of miR-223-3p and FAT1mRNA in tissues. Wound healing assay was used to detect the migration ability of liver cancer cells. Transwell assay was used to detect cells invasion ability. Dual-luciferase assay was used to detect the targeting relationship between miR-223-3p and FAT1. Western blot was used to detect the protein expression of EMT-related markers, E-cadherin and Vimentin.

Results FAT1 was highly expressed in liver cancer tissues and cells, while miR-223-3p was lowly expressed. Silencing FAT1 could inhibite the proliferation, migration, invasion and EMT of liver cancer cells. miR-223-3p targeted down-regulated the expression of FAT1, and inhibited the proliferation, migration, invasion and EMT of liver cancer cells by targeting FAT1.

Conclusion miR-223-3p regulates the occurrence and development of liver cancer cells by targeted down-regulating the expression of FAT1.
- FAT1,
- miR-223-3p,
- liver cancer,
- proliferation,
- migration and invasion,
- EMT
Citation: Jun Xu, Bei Wang, Zhengtao Liu, Mingchun Lai, Mangli Zhang, Shusen Zheng. miR-223-3p regulating the occurrence and development of liver cancer cells by targeting FAT1 gene[J]. Mathematical Biosciences and Engineering, 2020, 17(2): 1534-1547. doi: 10.3934/mbe.2020079

Related Papers:

Abstract

Objective To explore the mechanism of miR-223-3p regulating the occurrence and development of liver cancer cells by targeting FAT1 gene.

Methods Bioinformatics analysis was used to analyze the differentially expressed genes in liver cancer tissue chips. Forty-eight cases of liver cancer tissues and corresponding adjacent tissues were selected, and qRT-PCR was used to detect the expression of miR-223-3p and FAT1mRNA in tissues. Wound healing assay was used to detect the migration ability of liver cancer cells. Transwell assay was used to detect cells invasion ability. Dual-luciferase assay was used to detect the targeting relationship between miR-223-3p and FAT1. Western blot was used to detect the protein expression of EMT-related markers, E-cadherin and Vimentin.

Results FAT1 was highly expressed in liver cancer tissues and cells, while miR-223-3p was lowly expressed. Silencing FAT1 could inhibite the proliferation, migration, invasion and EMT of liver cancer cells. miR-223-3p targeted down-regulated the expression of FAT1, and inhibited the proliferation, migration, invasion and EMT of liver cancer cells by targeting FAT1.

Conclusion miR-223-3p regulates the occurrence and development of liver cancer cells by targeted down-regulating the expression of FAT1.

References

[1]	Y. A. Ghouri, I. Mian, B. Blechacz, Cancer review: Cholangiocarcinoma, J. Carcinog., 14 (2015).
[2]	J. Tejeda-Maldonado, I. García-Juárez, J. Aguirre-Valadez, A. González-Aguirre, M. Vilatobá-Chapa, A. Armengol-Alonso, Diagnosis and treatment of hepatocellular carcinoma: An update, World J. Hepatol., 7 (2015), 362-376.
[3]	A. Kinoshita, H. Onoda, N. Fushiya, K. Koike, H. Nishino, H. Tajiri, Staging systems for hepatocellular carcinoma: Current status and future perspectives, World J. Hepatol.,7 (2015), 406-424.
[4]	T. Kimhofer, H. Fye, S. Taylor-Robinson, E. Holmes, Proteomic and metabonomic biomarkers for hepatocellular carcinoma: A comprehensive review, Br. J. Cancer, 112 (2015), 1141-1156.
[5]	J. Dunnea, A. M. Hanby, R. Poulsom, T. A. Jones, Molecular cloning and tissue expression of FAT, the human homologue of the Drosophila fat gene that is located on chromosome 4q34-q35 and encodes a putative adhesion molecule, Genomics, 30 (1995), 207-223.
[6]	L. Ciani, A. Patel, N. D. Allen, C. ffrench-Constant, Mice lacking the giant protocadherin mFAT1 exhibit renal slit junction abnormalities and a partially penetrant cyclopia and anophthalmia phenotype. Mol. Cell Biol., 23 (2003), 3575-3582.
[7]	M. Katoh, Function and cancer genomics of FAT family genes, Int. J. Oncol., 41 (2012), 1913-1918.
[8]	N. Kwaepila, G. Burns, A. S. Leong, Immunohistological localisation of human FAT1 (hFAT) protein in 326 breast cancers. Does this adhesion molecule have a role in pathogenesis? Pathology, 38 (2006), 125-131.
[9]	C. E. de Bock, A. Ardjmand, T. J. Molloy, S. M. Bone, D. Johnstone, D. M Campbell, The Fat1 cadherin is overexpressed and an independent prognostic factor for survival in paired diagnosis-relapse samples of precursor B-cell acute lymphoblastic leukemia, Leukemia, 26 (2012), 918-926.
[10]	B. Dikshit, K. Irshad, E. Madan, N. Aggarwal, C. Sarkar, P. S. Chandra, FAT1 acts as an upstream regulator of oncogenic and inflammatory pathways, via PDCD4, in glioma cells, Oncogene, 32 (2013), 3798-3808.
[11]	D. Valletta, B. Czech, T. Spruss, K. Ikenberg, P. Wild, Arndt Hartmann, Regulation and function of the atypical cadherin FAT1 in liver cancer, Carcinogenesis., 35 (2014), 1407-1415.
[12]	C. H. Hung, Y. C. Chiu, C. H. Chen, T. H. Hu, MicroRNAs in hepatocellular carcinoma: Carcinogenesis, progression, and therapeutic target, Biomed. Res. Int., 2014 (2014).
[13]	C. H. Yu, C. F. Xu, Y. M. Li, Association of MicroRNA-223 expression with hepatic ischemia/reperfusion injury in mice, Dig. Dis. Sci., 54 (2009), 2362.
[14]	A. Aucher, D. Rudnicka, D. M. Davis, MicroRNAs transfer from human macrophages to hepato-carcinoma cells and inhibit proliferation, J. Immunol., 191 (2013), 6250-6260.
[15]	J. Xu, C. Wu, X. Che, L. Wang, D. Yu, T. Zhang, Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with liver cancer or chronic hepatitis, Mol. Carcinog., 50 (2), 136-142.
[16]	X. V. Qadir, W. Chen, C. Han, K. Song, J. Zhang, T. Wu, MiR-223 Deficiency Protects against Fas-Induced Hepatocyte Apoptosis and Liver Injury through Targeting Insulin-Like Growth Factor 1 Receptor, Am. J. Pathol., 185 (2015), 3141-3151.
[17]	S. Lee, S. Stewart, I. Nagtegaal, J. Luo, Y. Wu, G. Colditz, Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer, Cancer Res., 72 (2012), 4574-4586.
[18]	R. Hou, L. Liu, S. Anees, S. Hiroyasu, N. E. S. Sibinga, The Fat1 cadherin integrates vascular smooth muscle cell growth and migration signals, J. Cell. Biol., 173 (2006), 417-429.
[19]	M. J. Moeller, A. Soofi, G. S. Braun, X. Li, C. Watzl, W. Kriz, Protocadherin FAT1 binds Ena/VASP proteins and is necessary for actin dynamics and cell polarization, EMBO. J., 23 (2004), 3769-3779.
[20]	C. Srivastava, K. Irshad, B. Dikshit, P. Chattopadhyay, C. Sarkarm, D. K. Gupta, FAT1 modulates EMT and stemness genes expression in hypoxic glioblastoma, Int. J. Cancer, 142 (2018), 805-812.
[21]	X. Hua, Y. Zhai, P. Kong, H. Cui, T. Yan, J. Yang, FAT1 prevents epithelial mesenchymal transition (EMT) via MAPK/ERK signaling pathway in esophageal squamous cell cancer, Cancer Lett., 397 (2017), 83-93.
[22]	B. G. Giray, G. Emekdas, S. Tezcan, M. Ulger, M. S. Serin, O. Sezgin, Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive liver cancer, Mol. Biol. Rep., 41 (2014), 4513-4519.
[23]	Z. B. Han, L. Zhong, M. J. Teng, J. W. Fan, H. M. Tang, J. Y. Wu, Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantation, Mol. Oncol., 6 (2012), 445-457.

Reader Comments

Your name:*

Email:*
© 2020 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)